571 related articles for article (PubMed ID: 16513057)
41. Enzyme-linked immunoassay and electrophoretic separation of collagens secreted by cultured skin fibroblasts of patients with Ehlers-Danlos and Marfan syndromes.
Borisova NV; Safronova EE; Krasnopol'skaya KD; Blinnikova OE; Polyudov SA
Biomed Sci; 1991; 2(5):523-9. PubMed ID: 1840842
[TBL] [Abstract][Full Text] [Related]
42. Ehlers-Danlos syndrome and type III collagen abnormalities: a variable clinical spectrum.
Hamel BC; Pals G; Engels CH; van den Akker E; Boers GH; van Dongen PW; Steijlen PM
Clin Genet; 1998 Jun; 53(6):440-6. PubMed ID: 9712532
[TBL] [Abstract][Full Text] [Related]
43. Vascular Ehlers-Danlos syndrome.
Germain DP; Herrera-Guzman Y
Ann Genet; 2004; 47(1):1-9. PubMed ID: 15127738
[TBL] [Abstract][Full Text] [Related]
44. Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders.
Colombi M; Dordoni C; Chiarelli N; Ritelli M
Am J Med Genet C Semin Med Genet; 2015 Mar; 169C(1):6-22. PubMed ID: 25821090
[TBL] [Abstract][Full Text] [Related]
45. A case of Ehlers Danlos syndrome type VI.
Salavoura K; Valari M; Kolialexi A; Mavrou A; Kitsiou S
Genet Couns; 2006; 17(3):291-4. PubMed ID: 17100196
[TBL] [Abstract][Full Text] [Related]
46. The 2017 international classification of the Ehlers-Danlos syndromes.
Malfait F; Francomano C; Byers P; Belmont J; Berglund B; Black J; Bloom L; Bowen JM; Brady AF; Burrows NP; Castori M; Cohen H; Colombi M; Demirdas S; De Backer J; De Paepe A; Fournel-Gigleux S; Frank M; Ghali N; Giunta C; Grahame R; Hakim A; Jeunemaitre X; Johnson D; Juul-Kristensen B; Kapferer-Seebacher I; Kazkaz H; Kosho T; Lavallee ME; Levy H; Mendoza-Londono R; Pepin M; Pope FM; Reinstein E; Robert L; Rohrbach M; Sanders L; Sobey GJ; Van Damme T; Vandersteen A; van Mourik C; Voermans N; Wheeldon N; Zschocke J; Tinkle B
Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):8-26. PubMed ID: 28306229
[TBL] [Abstract][Full Text] [Related]
47. Ehlers-Danlos Syndrome, classical type: case management.
Whitelaw SE
Pediatr Nurs; 2003; 29(6):423-6. PubMed ID: 14743836
[TBL] [Abstract][Full Text] [Related]
48. [Ehlers-Danlos syndrome IV: phenotype variation].
Engels CH; van Dongen PW; Boers GH; Steijlen PM; Hamel BC
Ned Tijdschr Geneeskd; 1997 Feb; 141(6):296-8. PubMed ID: 9148166
[TBL] [Abstract][Full Text] [Related]
49. Assessment of skin extensibility and joint hypermobility in patients with spontaneous cervical artery dissection and Ehlers-Danlos syndrome.
Heidbreder AE; Ringelstein EB; Dittrich R; Nabavi D; Metze D; Kuhlenbäumer G
J Clin Neurosci; 2008 Jun; 15(6):650-3. PubMed ID: 18400501
[TBL] [Abstract][Full Text] [Related]
50. Characterization of 11 new mutations in COL3A1 of individuals with Ehlers-Danlos syndrome type IV: preliminary comparison of RNase cleavage, EMC and DHPLC assays.
Giunta C; Steinmann B
Hum Mutat; 2000 Aug; 16(2):176-7. PubMed ID: 10923041
[TBL] [Abstract][Full Text] [Related]
51. Ehlers-Danlos syndrome type IV: cosegregation of the phenotype to a COL3A1 allele of type III procollagen.
Tsipouras P; Byers PH; Schwartz RC; Chu ML; Weil D; Pepe G; Cassidy SB; Ramirez F
Hum Genet; 1986 Sep; 74(1):41-6. PubMed ID: 2875936
[TBL] [Abstract][Full Text] [Related]
52. A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen.
Narcisi P; Richards AJ; Ferguson SD; Pope FM
Hum Mol Genet; 1994 Sep; 3(9):1617-20. PubMed ID: 7833919
[TBL] [Abstract][Full Text] [Related]
53. Abnormal collagen fibril structure in the gravis form (type I) of Ehlers-Danlos syndrome.
Vogel A; Holbrook KA; Steinmann B; Gitzelmann R; Byers PH
Lab Invest; 1979 Feb; 40(2):201-6. PubMed ID: 431039
[TBL] [Abstract][Full Text] [Related]
54. The clinical presentation of Ehlers-Danlos syndrome.
Lawrence EJ
Adv Neonatal Care; 2005 Dec; 5(6):301-14. PubMed ID: 16338669
[TBL] [Abstract][Full Text] [Related]
55. Vascular aspects of the Ehlers-Danlos Syndromes.
Malfait F
Matrix Biol; 2018 Oct; 71-72():380-395. PubMed ID: 29709596
[TBL] [Abstract][Full Text] [Related]
56. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture.
Pope FM; Narcisi P; Nicholls AC; Germaine D; Pals G; Richards AJ
Br J Dermatol; 1996 Aug; 135(2):163-81. PubMed ID: 8881656
[TBL] [Abstract][Full Text] [Related]
57. Altered secretion of type III procollagen in a form of type IV Ehlers-Danlos syndrome. Biochemical studies in cultured fibroblasts.
Byers PH; Holbrook KA; Barsh GS; Smith LT; Bornstein P
Lab Invest; 1981 Apr; 44(4):336-41. PubMed ID: 6259441
[TBL] [Abstract][Full Text] [Related]
58. Vascular Ehlers-Danlos syndrome: a case with fatal outcome.
Morais P; Mota A; Eloy C; Lopes JM; Torres F; Palmeiro A; Tavares P; Azevedo F
Dermatol Online J; 2011 Apr; 17(4):1. PubMed ID: 21549076
[TBL] [Abstract][Full Text] [Related]
59. [Collagen type I, III, IV and V and fibronectin in skin biopsies of patients with Ehlers-Danlos syndrome and cutis laxa].
Shekhonin BV; Semiachkina AN; Makkaev KhM; Domogatskiĭ SP; Idel'son GL
Arkh Patol; 1988; 50(12):41-8. PubMed ID: 3074749
[TBL] [Abstract][Full Text] [Related]
60. Molecular genetics in classic Ehlers-Danlos syndrome.
Malfait F; De Paepe A
Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):17-23. PubMed ID: 16278879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
